Heart failure medication optimisation plan (PDF, 139MB)
The heart failure medication optimisation plan (June 2022) replaces the heart failure medication titration plan (2017). The plan is initiated by a treating team and sent to GPs. The plan addresses the implementation of 4 drug classes, diuretics and highlights iron monitoring.
To adapt the plan for local use outside of Queensland Health, please register here and acknowledge the source of the plan as follows: Reproduced with permission from Queensland Health. Source https://www.health.qld.gov.au/__data/assets/pdf_file/0018/428121/Medn_Titration.pdf. For further enquiries please email: firstname.lastname@example.org
The Fluid Action Plan is a flexible diuretic plan which can be given to patients who are able to manage dose changes.
Sacubitril/valsartan (Entresto) Fact Sheet (PDF, 267kB)
The sacubitril-valsartan (Entresto) fact sheet provides prescribing information for a new drug class called angiotensin receptor-neprilysin inhibitor (ARNI). The Pharmaceutical Benefits Scheme (PBS) recommends Entresto for heart failure patients with a reduced ejection fraction.
The HEART online toolkit provides nurses, allied health, pharmacists and doctors with evidence-based resources to assist the management of patients with chronic heart failure and cardiovascular disease.
Heart Failure: End-stage management guideline (PDF, 536kB)
The Queensland Health end-stage heart failure management guideline will help the health care team to recognise when a patient is approaching end-stage heart failure. The guide provides advice on how to promote quality of life and includes approaches to medication management, implantable cardiac defibrillator (ICD) deactivation, and managing common symptoms (dyspnoea, oedema, pain, anxiety and depression, constipation, nausea and vomiting, anorexia and cachexia, and fatigue).
This is a practical guide to help clinicians (particularly exercise therapists) implement virtual exercise and education programs for those with cardiac conditions (including heart failure) and chronic pulmonary disease.